Cipla Secures Rights to Investigational HER2 Cancer Therapy TQB2102 Across India and Emerging Markets
The agreement, announced on August 31, 2026, has been signed with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of Sino Biopharmaceutical Limited. Under the exclusive licence and supply arrangement, Cipla will take responsibility for local clinical development, regulatory submissions and eventual commercialisation of TQB2102 in the licensed territories, while Chia Tai Tianqing will continue to manufacture and supply the investigational medicine.